Bevacizumab for metastatic colorectal cancer: A global cost-effectiveness analysis
- Daniel A. Goldstein*
- , Qiushi Chen
- , Turgay Ayer
- , Kelvin K.W. Chan
- , Kiran Virik
- , Ariel Hammerman
- , Baruch Brenner
- , Christopher R. Flowers
- , Peter S. Hall
*Corresponding author for this work
- Rabin Medical Center Israel
- Emory University
- Georgia Institute of Technology
- University of Toronto
- Canadian Centre for Applied Research in Cancer Control
- University of Tasmania
- Clalit Health Services
- University of Edinburgh
Research output: Contribution to journal › Article › peer-review
33
Scopus
citations